Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyrizon Eyes $3.15B Epilepsy Market with Rescue Drug in Preclinical Stage
Details : Intranasal Benzodiazepines (BZDs) is being developed by Polyrizon as a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyrizon Advances Preclinical Epilepsy Rescue Treatment Studies
Details : A preclinical study has been initiated for intranasal Benzodiazepines (BZDs), as a first-line treatment for acute repetitive seizures (ARS) and status epilepticus.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innocan Pharma Announces Positive Safety Results of LPT-CBD in Minipigs
Details : LPT-CBD is a monthly injectable treatment consisting cannbidiol, it is currently being investigated for chronic pain.
Product Name : LPT-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innocan Focuses on Positive FDA Engagement and Market Demand
Details : LPT-CBD is a monthly injectable treatment consisting cannbidiol, it is currently being investigated for chronic pain.
Product Name : LPT-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 11, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Details : LPT CBD (cannabinoid) is a loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into blood stream. It is being evaluated for chronic pain management.
Product Name : LPT-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 06, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SCI-160,N-Acylethanolamine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Polyrizon
Deal Size : $6.0 million
Deal Type : Licensing Agreement
SciSparc Grants Rights For Pain Therapy in $6M Biotech Agreement
Details : Under the agreement, SciSparc out-licensed its SCI-160 program, an innovative, proprietary synthetic combination of cannabinoids and N- acylethanolamines, being developed for the treatment of pain.
Product Name : SCI-160
Product Type : Other Small Molecule
Upfront Cash : $3.0 million
August 28, 2024
Lead Product(s) : SCI-160,N-Acylethanolamine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Polyrizon
Deal Size : $6.0 million
Deal Type : Licensing Agreement
Lead Product(s) : SCI-160,N-Acylethanolamine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Polyrizon
Deal Size : $6.0 million
Deal Type : Licensing Agreement
SciSparc Signs Global Out-Licensing Deal For Pain Therapy Worth $3 Million
Details : SciSparc out-licenses its SCI-160 program for the treatment of pain to Polyrizon. SCI-160 is an innovative, proprietary synthetic combination of cannabinoids and N-acylethanolamines.
Product Name : SCI-160
Product Type : Other Small Molecule
Upfront Cash : $3.0 million
August 19, 2024
Lead Product(s) : SCI-160,N-Acylethanolamine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Polyrizon
Deal Size : $6.0 million
Deal Type : Licensing Agreement
Lead Product(s) : SCI-160
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $6.0 million
Deal Type : Licensing Agreement
SciSparc Signs Letter of Intent for Global Out-Licensing of Pain Treatment for $6M
Details : SciSparc out-licensing of its SCI-160 program, whic is an innovative, proprietary synthetic cannabinoid formulation. It is being evaluated in the early-stage clinical trial for the treatment of pain.
Product Name : SCI-160
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 17, 2024
Lead Product(s) : SCI-160
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $6.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innocan LPT-CBD Shows Potential for Neurological Disorders, According to New Study
Details : LPT-CBD (cannabidiol) is a CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of patients suffering from neurological diseases.
Product Name : LPT-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 03, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innocan Pharma Begins FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Details : LPT CBD (cannabinoid) is a loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. It is being evaluated for chronic pain management.
Product Name : LPT-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 22, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable